Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800731 | 0.71 | HTR2C (0.46) | POLBCHRM3ALDH1A1CCR2NAMPT | |
| SCHEMBL3447475 | 0.70 | P2RX1 (0.54) | POLBALDH1A1HTR2C | |
| SCHEMBL6798519 | 0.66 | LMNA (0.44) | POLBALDH1A1TP53 | |
| SCHEMBL25936926 | 0.66 | POLB (0.59) | POLBCHRM3ALDH1A1CCR2TP53 | |
| SCHEMBL11712708 | 0.66 | HDAC6 (0.56) | POLBCHRM3ALDH1A1CCR2TP53 | |
| Hydrochloric Acid SCHEMBL11715522 | 0.65 | HDAC6 (0.55) | POLBCHRM3ALDH1A1CCR2TP53 | |
| SCHEMBL5513102 | 0.64 | POLB (0.56) | POLBCHRM3ALDH1A1CCR2NAMPT | |
| SCHEMBL15054310 | 0.64 | SMYD3 (0.54) | POLBCHRM3ALDH1A1CCR2NAMPT | |
| SCHEMBL2679794 | 0.63 | LMNA (0.61) | POLBALDH1A1TP53TP53BP1 | |
| SCHEMBL4742356 | 0.63 | POLB (0.62) | POLBCHRM3ALDH1A1CCR2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | POLB 3627/4885CHRM3 657/4885ALDH1A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.